Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.
Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.
Bills each patient's insurer for emergency visits, and much of its income comes from out-of-network claims, which pay more than contracted rates but are negotiated or disputed afterwards, so collections vary. Facilities are concentrated in Texas. It became public through a 2022 merger with Clinigence Holdings.
Moat: narrow (regulatory licence, distribution). State-licensed micro-hospital model provides emergency access in underserved areas, though model draws billing scrutiny.
Headquarters: Houston, Texas · Founded: 2011 · Employees: 944
Size Nutex Health (NUTX) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.19B, the 2128th largest of 3,085 United States companies the cockpit tracks. Shares closed at $172.74 on 18 Nov 2026.
Performance Over six months the shares gained 42.1%, against +12.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 18.8% over the last twelve months (peer median +7.9%); the operating margin is 39.0% (peer median 3.5%).
Valuation It trades at 6.5× forward earnings against a peer median of 25.3× (cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +253%, so the hurdle is -271 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 24.7 points above its cost of capital (7.7% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $797M | $875M | $480M | $248M | $219M |
| Revenue growth | — | +82% | +94% | +13% | — |
| Gross profit | $381M | $444M | $196M | $34.8M | $13.5M |
| EBITDA | $333M | $296M | $157M | $16.3M | $8.62M |
| Net income | $165M | $70.8M | $52.1M | -$45.8M | -$425M |
| Free cash flow | $248M | $246M | $20.8M | -$8.24M | $36.0M |
| Capital expenditure | $10.4M | $2.53M | $2.30M | $9.50M | $14.6M |
| Total debt | $365M | $351M | $340M | $276M | $267M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nutex Health NUTX | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% |
| HCA Healthcare HCA | $99.5B | +20% | +6% | 15% | 15.6× | 3.1% |
| Community Health Systems CYH | n/a | -34% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NUTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.2% | +1.3% | 3rd lowest of 21 |
| 6-month return | +42.1% | +12.3% | 4th highest of 21 |
| Distance from 52-week high | -23.6% | -22.4% | 11th highest of 21 |
| Revenue growth (TTM) | -18.8% | +7.9% | 2nd lowest of 21 |
| Operating margin | 39.0% | 3.5% | highest of 21 |
| Forward P/E | 6.5× | 25.3× | cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -18.0% | 8.5% | least demanding of 15 |
| Growth delivered (Del g) | +253.5% | +9.4% | highest of 15 |
| Hurdle (Req g minus delivered) | -271.5 pp | -0.4 pp | least demanding of 15 |
| ROIC minus cost of capital | +24.7 pp | -3.8 pp | highest of 19 |
| EV / EBITDA | 4.2× | 10.1× | cheapest of 15 |
| Net debt / EBITDA | 0.3× | 2.0× | 5th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |